BioCardia (BCDA) Cash from Operations Growth (3y) (2015 - 2026)
Powered by 
Analysis
BioCardia (BCDA) Cash from Operations Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 61.18% |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.34 Bn | 55.72 Mn | 13.50% |
| 4 | Legend Biotech | 3.56 Bn | 2.60 Bn | 251.50 Mn | 40.17% |
| 5 | uniQure | 3.01 Bn | 3.01 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - | - |
| 7 | Precigen | 2.36 Bn | 2.36 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.19 Bn | 1.40 Bn | 251.87 Mn | 53.44% |
| 9 | Vericel | 1.96 Bn | 1.80 Bn | 56.40 Mn | 16.67% |
| 10 | BioCardia | 13.18 Mn | 9.06 Mn | - | 18.04% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.04% |
| Mar 31, 2026 | 13.46% |
| Dec 31, 2025 | 5.90% |
| Sep 30, 2025 | 5.89% |
| Jun 30, 2025 | 14.57% |
| Mar 31, 2025 | 17.80% |
| Dec 31, 2024 | 6.48% |
| Sep 30, 2024 | 0.41% |
| Jun 30, 2024 | 22.92% |
| Mar 31, 2024 | 6.69% |
| Dec 31, 2023 | 18.48% |
| Sep 30, 2023 | 12.53% |
| Jun 30, 2023 | -10.38% |
| Mar 31, 2023 | 5.08% |
| Dec 31, 2022 | 2.73% |
| Sep 30, 2022 | -10.87% |
| Jun 30, 2022 | -5.51% |
| Mar 31, 2022 | -5.72% |
| Dec 31, 2021 | 2.86% |
| Sep 30, 2021 | -9.57% |